A treatment can be quite effective in a specific subset without being effective in the whole cancer type, e.g., Herceptin is very effective in HER2+ breast cancer but not effective in breast cancer overall (Hudziak et al., 1989), so it is important to identify the subsets of cancers that may benefit from IDO-1 inhibitors. The gene discussed is ERBB2; the disease is breast carcinoma.